Hartford Business Journal

HBJ121123UF

Issue link: https://nebusinessmedia.uberflip.com/i/1512766

Contents of this Issue

Navigation

Page 4 of 35

HARTFORDBUSINESS.COM | DECEMBER 11, 2023 5 Deal Watch Carter Winstanley is the lead developer of the 101 College St. bioscience tower in New Haven that is set to debut early next year. In the background is 100 College St., another New Haven bioscience tower that Winstanley's firm developed. HBJ PHOTO | STEVE LASCHEVER New Haven's 101 College St. bioscience tower nears debut, as demand for lab space slows By Hanna Snyder Gambini hgambini@hartfordbusiness.com T he 101 College St. building in the heart of New Haven is set to debut in early 2024, providing new research and labo- ratory space for the city's growth- minded bioscience industry. Two-year-old construction on the 525,000-square-foot life sciences tower is wrapping up. Tenant fit-outs are now underway, after core and shell work was completed in September. The building's first tenant, Alexion Pharmaceuticals, is set to move in at the start of next year, with another major tenant, BioLabs, up and running by Feb. 1, said Carter Winstanley, principal of project developer Winstanley Enterprises. The 10-story building was 60% to 70% leased when ground was broken on June 1, 2021. When the property debuts, 90% of its space will be leased to life science companies, including Arvinas, as well as industry group BioCT and Yale University. Interest in the property reflects New Haven's attraction as the state's bioscience hub, helped significantly by the presence of Yale, experts say. However, the building will come online at a time when demand for lab space in New Haven, the state and nationwide has declined due to broader economic conditions, including a high interest rate environ- ment that has slowed venture capital investment, which serves as the lifeblood of the bioscience industry, said Robert H. Motley, a senior director at real estate services firm Cushman & Wakefield. Also dampening the sector's short-term growth is continued fallout from this year's collapse of Silicon Valley Bank, a key lender and money manager for the biosci- ence industry, Motley said. "How would I characterize the demand for life science space in New Haven? Right now, it's a little slow," Motley said. About 12.1% of New Haven's 3.1 million square feet of lab space was vacant at the end of the second quarter, according to Cushman & Wakefield. Comparatively, Greater New Haven's 10.8 million square feet of office space was 17.5% vacant at the end of the second quarter, Cushman & Wakefield data shows. Winstanley said demand for lab space naturally ebbs and flows over time. "At this moment, we are experi- encing a slowdown in the market due to a decrease in the availability of both public and private investment dollars," Winstanley said. But the decrease is being offset, in part, by new ventures being spun out of Yale, he added, a trend that is expected to continue — and potentially accelerate — in the years ahead. New Haven's transformation Carter Winstanley has been a key player in helping transform New Haven into a life sciences hub. He was recently appointed to the board of directors of BioCT, a statewide life sciences group. A quarter-century ago, his firm — Winstanley Enterprises — acquired for $27.5 million the largely vacant 518,940-square-foot Southern New England Telephone Co. office building, at 300 George St., and rede- veloped the property into life science and medical office space that is now fully leased by Yale University and Yale New Haven Hospital. Yale University in late November bought 300 George St. for $139.7 million, more than five times the price Winstanley paid for the building in 2000, city land records show. In 2015, Winstanley Enterprises debuted its 513,000-square-foot, 14-story office and laboratory building at 100 College St., next to its new property at 101 College. Since then, other bioscience proj- ects have been built, proposed or are underway, including several in nearby Science Park as well as "Square 10," a proposed 11-story, 200,000-square- foot bioscience building with medical labs for Yale and other companies on the old coliseum site on South Orange Street. Landlord The Hurley Group a few years ago converted its 8-story, 105,500-square-foot Class B office building at 55 Church St., into the Elm City Bioscience Center, now leased by several life science companies. "What we've found is, the more we build and bring space online, the more it creates essentially a center of gravity for tenants in the region," said Winstanley, whose firm owns more than 1 million square feet of lab space in New Haven. New research and development space plays a pivotal role in creating a life sciences hub that can draw talent from around the globe, Winstanley said. "It's an industry that once it takes hold, it does really feed on itself," he said. "Additionally, what we really like to see is this industry has solid reemployment opportunities for indi- viduals who work in this sector." The life sciences industry has a high failure rate, so having a strong base of bioscience companies and startups gives talent the chance to stay in the market locally. Helping that effort will be 101 College St.'s 50,000 square feet of incubator space, which is important in the recruitment of life science compa- nies because it helps startups defray lab space costs. BY THE NUMBERS New Haven's life sciences real estate footprint 13 The number of buildings with lab space. 3.18M Total square footage of lab space in New Haven. 386,900 Total lab space square footage that is currently vacant. 12.17% Lab space vacancy rate. Source: Cushman & Wakefield Robert Motley

Articles in this issue

Links on this page

Archives of this issue

view archives of Hartford Business Journal - HBJ121123UF